Ani Pharmaceuticals Inc (ANIP) — Who Owns This Stock? 13F Breakdown (Q2 2026)

ANIP ranks #2070 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

308 institutions disclose a position in ANIP, but none treat it as a major bet — even Jones Hill Capital LP, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

Versant Capital Management, Inc has added to its ANIP position for two straight quarters, increasing it by $16.0K to reach $31.0K today.

Oliver Luxxe Assets LLC has trimmed its ANIP position for two straight quarters, cutting it by $788.4K while still holding $1.6M.

ANIP is up 0% today, and institutions have been net buyers of $215.6M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ANIP posted net income of $108.3M over the trailing twelve months, and currently trades at a P/E of 14.2.

• Profitable — net income of $108.3M over the trailing twelve months
• Revenue grew 30.9% year over year
• Net income improved year over year, from -$10.2M to $108.3M
• Generated $185.2M in positive operating cash flow
• Current ratio of 2.71x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.66x equity — within a conventional range